Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market buyback of 24,900 H shares on 12 May 2026. The transaction was completed on the Hong Kong Stock Exchange at prices ranging between HKD 31.50 and HKD 32.50, with a volume-weighted average payment of HKD 31.83 per share, bringing the aggregate consideration to HKD 0.79 million.

Following the repurchase, the number of issued shares (excluding treasury shares) fell by 0.018% to 135.65 million. Treasury shares increased from 547,300 to 572,200, while the company’s total issued share count remained unchanged at 136.22 million.

The buyback formed part of the mandate approved on 12 February 2026, which permits the company to repurchase up to 13.62 million shares. Cumulative purchases under this mandate now stand at 572,200 shares, representing 0.42% of the issued share base on the mandate date.

Under Hong Kong listing rules, Hanx Bio is restricted from issuing new shares or disposing of treasury shares until 11 June 2026, 30 days after the latest repurchase.